Polycythemia Vera (PV)

Hematology
3
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

PharmaEssentia
PharmaEssentiaMA - Burlington
3 programs
1
2
P1101Phase 31 trial
P1101Phase 31 trial
P1101Phase 21 trial
Active Trials
NCT04182100CompletedEst. Mar 2021
NCT06002490CompletedEst. Jul 2024
NCT04655092RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharmaEssentiaP1101
PharmaEssentiaP1101
PharmaEssentiaP1101

Clinical Trials (3)

A Study to Evaluate P1101 in Japanese PV Patients

Start: Oct 2023Est. completion: Jul 2024
Phase 3Completed

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Start: Jan 2021Est. completion: Jun 2026
Phase 3Recruiting

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Start: Dec 2019Est. completion: Mar 2021
Phase 2Completed

Related Jobs in Hematology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space